Drugs / Bone morphogenetic protein 7
Bone morphogenetic protein 7
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01133613 | May 2010 → Oct 2011 | osteoarthritis, knee | Stryker Biotech | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02655120 | Mar 2005 → May 2017 | avascular necrosis | University Hospital, Lille | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01111045 Comparator | Apr 2010 → Aug 2011 | osteoarthritis, knee | Stryker Biotech | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone morphogenetic protein 7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01133613 ↗ |
| Known as | 38A BMP-7 | “Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee” NCT01133613 ↗ |
| Known as | BMP-7 | “Dose Finding Study of Bone Morphogenetic Protein 7 (BMP-7) in Subjects With Osteoarthritis (OA) of the Knee” NCT01111045 ↗ |
| Known as | OP1 | “The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 ( OP1) .” NCT02655120 ↗ |
| Modality | Protein / enzyme biologic | “recombinant BMP7” NCT02655120 ↗ |
| Route | Other | “0.03 mg/ml BMP-7, single intraarticular knee injection” NCT01111045 ↗ |